|
- Edwards Lifesciences - the leader in heart valves hemodynamic . . .
We focus on improving patient lives and being responsible corporate citizens
- Costa Rica - Edwards Lifesciences
Nuestras dos instalaciones están ubicadas en Cartago y albergan una variedad de comodidades para beneficiar a nuestros empleados Nuestra hermosa cafetería cuenta con deliciosas opciones tanto para el desayuno como para el almuerzo, así como también con una gran cantidad de espacio en refrigeradores si prefieres traer tus comidas desde casa Nuestro Centro de Bienestar está completamente
- Clinical Affairs - Edwards Lifesciences
Through the rigorous process of clinical research trials, our purpose is to gather clinical evidence and data that proves the efficacy and safety of our breakthrough, lifesaving technologies Working in partnership with physicians and clinical investigators, our Clinical Affairs team uses pioneering research methodologies to secure the best possible therapies for patients In close partnership
- Transcatheter Mitral Tricuspid Technologies | Edwards Lifesciences
Learn about early detection, management of conditions, and various treatment options
- Edwards Lifesciences Reports First Quarter Results
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar 31, 2025 Recent Highlights Q1 sales grew 6 2% to $1 41 billion, or 7 9% adjusted 1 Q1 TAVR sales grew 3 8%; constant currency 1 sales grew 5 4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0 62 2 ; adjusted 1 EPS of $0 64 SAPIEN
- Press Releases | Edwards Lifesciences
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
- EVOQUE Tricuspid Valve Replacement | Edwards Lifesciences
The TRISCEND II trial is a prospective multi-center randomized controlled trial evaluating the safety and effectiveness of transcatheter tricuspid valve replacement with the EVOQUE system plus optimal medical therapy compared to optimal medical therapy alone in patients with symptomatic severe TR These data pertain to the entire cohort of 400 patients at 1 year
- Sapien M3 | Edwards Lifesciences
Trial objective Establish the safety and effectiveness of the SAPIEN M3 system in subjects with symptomatic, at least 3+ MR for whom commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomical, or technical considerations Primary endpoint Non-hierarchical composite of death heart failure rehospitalization at 1 year Secondary
|
|
|